Medigene AG Namen-Akt. nach Kapitalherabsetzung MDGEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.76
- Day Range
- $2.43–2.43
- 52-Week Range
- $1.50–2.84
- Bid/Ask
- $1.52 / $1.77
- Market Cap
- $59.69 Mil
- Volume/Avg
- 500 / 532
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 86
- Website
- https://www.medigene.com
Comparables
Valuation
|
Metric
|
MDGEF
|
HPHA
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.49 | 3.74 | 2.59 |
Price/Sales | 8.91 | 15.18 | 30.43 |
Price/Cash Flow | — | — | — |
Price/Earnings
MDGEF
HPHA
NYKD
Financial Strength
|
Metric
|
MDGEF
|
HPHA
|
NYKD
|
|---|---|---|---|
Quick Ratio | 2.47 | 2.18 | 7.91 |
Current Ratio | 2.53 | 2.92 | 8.04 |
Interest Coverage | −29.52 | −34.44 | −235.75 |
Quick Ratio
MDGEF
HPHA
NYKD
Profitability
|
Metric
|
MDGEF
|
HPHA
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −37.93% | −22.72% | −19.18% |
Return on Equity (Normalized) | −53.96% | −38.22% | −26.31% |
Return on Invested Capital (Normalized) | −47.20% | −32.03% | −30.96% |
Return on Assets
MDGEF
HPHA
NYKD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yrtrgpvst | Kjwbf | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nmldhmxg | Rtssb | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qbtvfkzc | Ggjybs | $103.3 Bil | |
MRNA
| Moderna Inc | Psxfdsr | Rgyg | $48.1 Bil | |
ARGX
| argenx SE ADR | Lflqkcdds | Jwmfd | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Zhsbcwgl | Qwsp | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bdtpskt | Wwlhd | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vzxbhjph | Vtygk | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gxsxznzzq | Bdflcx | $12.7 Bil | |
INCY
| Incyte Corp | Wltvqnp | Vhnfcm | $11.9 Bil |